Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations

August 23, 2019 12:16 AM UTC

Innovent, Lilly in third biologics deal
Innovent Biologics Inc. (HKEX:1801) in-licensed Chinese rights to OXM3 from Eli Lilly and Co. (NYSE:LLY) to treat diabetes. The oxyntomodulin analog -- a dual agonist of GLP-1R and GCGR -- also has the potential to be developed for obesity and non-alcoholic steatohepatitis (NASH). Financial terms were undisclosed. This is Innovent's third collaboration with Lilly; the first two deals largely centered on co-developing biologics from Innovent's pipeline (see "Sourcing Biologics in China").

Sobi sells Priority Review voucher
Swedish Orphan Biovitrum AB (SSE:SOBI) sold a Priority Review voucher to AstraZeneca plc (LSE:AZN; NYSE:AZN) for $95 million. Sobi gained the voucher in its CHF515 million ($519.2 million) acquisition of a company focused on the development of Gamifant emapalumab; the voucher was granted with Gamifant's approval in November for hemophagocytic lymphohistiocytosis (see "Sobi Buying Novimmune Assets as it Refocuses R&D")...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article